Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Recurrence 2Urethral Neoplasms 1Ureteral Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Gemcitabine 6Docetaxel 3durvalumab 2Mitomycin 2viscum album peptide 1tremelimumab 1pembrolizumab 1erdafitinib 1avelumab 1VPM1002 recombinant BCG vaccine 1Neoadjuvant Therapy 1Monatide (IMS 3015) 1Mitozytrex 1House Calls 1Home Care Services 1Dihematoporphyrin Ether 1DDMS 1Cystoscopy 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1Administration, Intravesical 1ALT-803 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Muscle Invasive Bladder Neoplasms × ALT-801 × Clear all
NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

Phase 1/2 Terminated
12 enrolled 13 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡